IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

IPSEN (OTCMKTS:IPSEY)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $47.11, but opened at $44.81. IPSEN shares last traded at $44.81, with a volume of 170 shares changing hands.

Analyst Upgrades and Downgrades

IPSEY has been the topic of a number of recent analyst reports. Zacks Research raised shares of IPSEN to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

IPSEN Stock Performance

The company has a 50 day moving average price of $46.28 and a 200-day moving average price of $45.15.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).